Medtronic plc received 510(k) clearance from the U.S. FDA for its noninvasive cardiac mapping system.

The company will employ a strategic rollout of the technology in the geographies where it is cleared.

The CardioInsight noninvasive 3D mapping system is used for mapping of irregular heart rhythms in the upper and lower chambers of the heart. It also provides electroanatomic 3D maps of the heart.